WO2026053122 - METHODS OF TREATING RETINOID RESPONSIVE CANCERS
National phase entry is expected:
Publication Number
WO/2026/053122
Publication Date
12.03.2026
International Application No.
PCT/IB2025/058863
International Filing Date
03.09.2025
Title **
[English]
METHODS OF TREATING RETINOID RESPONSIVE CANCERS
[French]
PROCÉDÉS DE TRAITEMENT DE CANCERS SENSIBLES AUX RÉTINOÏDES
Applicants **
DANA-FARBER CANCER INSTITUTE, INC.
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
Inventors
LOOK, Albert Thomas
WEICHERT-LEAHY, Nina
DURBIN, Adam
ABRAHAM, Brian
ZIMMERMAN, Mark
Priority Data
63/690,532
04.09.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2281 | |
| EPO | Filing, Examination, Granting | 11573 | |
| Japan | Filing, Examination, Granting | 2356 | |
| South Korea | Filing, Examination, Granting | 2433 | |
| USA | Filing, Examination, Granting | 4940 |
Total:
23,583
Contact Us
Abstract[English]
There is provided a method of treating retinoid responsive cancer in a patient, comprising administering to said patient a therapeutically effective amount of one or more compounds which, individually or collectively, (i) induce and/or maintain tri-methylation of H3K27 within chromatin comprising one or more genes which encode regulatory elements of the adrenergic proliferative core regulatory circuitry of retinoid responsive cancer cells; and (ii) reduce and/or prevent tri-methylation of H3K27 within chromatin comprising one or more genes which encode ganglioside synthases in retinoid responsive cancer cells.[French]
L'invention concerne un procédé de traitement de cancers sensibles aux rétinoïdes chez un patient, comprenant l'administration audit patient d'une quantité thérapeutiquement efficace d'un ou de plusieurs composés qui, individuellement ou collectivement, (i) induisent et/ou maintiennent la tri-méthylation de H3K27 à l'intérieur de la chromatine comprenant un ou plusieurs gènes qui codent des éléments régulateurs de l'ensemble de circuits régulateurs à noyau prolifératif adrénergique des cellules cancéreuses sensibles aux rétinoïdes ; et (ii) réduisent et/ou empêchent la tri-méthylation de H3K27 à l'intérieur de la chromatine comprenant un ou plusieurs gènes qui codent pour des gangliosides synthases dans des cellules cancéreuses sensibles aux rétinoïdes.